Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) EBITDA (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed EBITDA for 6 consecutive years, with -$4.3 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 70.15% to -$4.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$15.2 million, a 25.24% decrease, with the full-year FY2024 number at -$10.6 million, up 36.69% from a year prior.
  • EBITDA was -$4.3 million for Q3 2025 at Vivos Therapeutics, up from -$4.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $8.8 million in Q4 2021 to a low of -$6.8 million in Q2 2022.
  • A 5-year average of -$3.6 million and a median of -$4.1 million in 2023 define the central range for EBITDA.
  • Biggest YoY gain for EBITDA was 240.69% in 2021; the steepest drop was 220.42% in 2021.
  • Vivos Therapeutics' EBITDA stood at $8.8 million in 2021, then crashed by 168.82% to -$6.1 million in 2022, then skyrocketed by 32.64% to -$4.1 million in 2023, then skyrocketed by 36.19% to -$2.6 million in 2024, then crashed by 66.23% to -$4.3 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's EBITDA are -$4.3 million (Q3 2025), -$4.6 million (Q2 2025), and -$3.7 million (Q1 2025).